Navigation Links
Commonly used 3-drug regimen for idiopathic pulmonary fibrosis found harmful
Date:10/21/2011

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns. The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC) had worse outcomes than those who received placebos, or inactive substances.

"These findings underscore why treatments must be evaluated in a rigorous manner," said Susan B. Shurin, M.D., acting director of the NHLBI. "This combination therapy is widely used in patients with IPF, but has not previously been studied in direct comparison to a placebo for all three drugs."

The interim results from this study showed that compared to placebo, those assigned to triple therapy had greater mortality (11 percent versus 1 percent), more hospitalizations (29 percent versus 8 percent), and more serious adverse events (31 percent versus 9 percent) and also had no difference in lung function test changes. Participants randomly assigned to the triple- therapy arm also remained on their assigned treatment at a much lower rate (78 percent adherence versus 98 percent adherence).

"Anyone on some combination of these medications with questions or concerns should consult with their health care provider and not simply stop taking the drugs," said Ganesh Raghu, M.D., professor of medicine at the University of Washington, Seattle and a co-chair of this IPF study. "It is important to realize that these results definitively apply only to patients with well-defined IPF and not to people taking a combination of these drugs for other lung diseases or conditions."

The other two study arms, or intervention groups, of this IPF trial comparing NAC alone to placebo alone will continue. In stopping this part of the trial, the NHLBI accepted the
'/>"/>

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Commonly used supplement may improve recovery from spinal cord injuries
2. Commonly used defibrillators raise risk of problems
3. Study shows PRP, commonly used technique to improve healing, doesnt work in rotator cuff surgery
4. Hepatitis C patients likely to falter in adherence to treatment regimen over time, Penn study shows
5. Integrating medication regimens into daily routines can improve adherence
6. Best post-transplant drug regimen identified for patients with new kidneys
7. Asian lung cancer patient survival exceeds Caucasians on multiple regimens
8. Early success of anti-HIV preventive oral drug regimen is promising, but questions remain
9. 6-month drug regimen cuts HIV risk for breastfeeding infants, NIH study finds
10. Bleeding Risk With Plavix-Aspirin Regimen May Be Serious
11. Studies Tout Alternative HIV Regimens for Women, Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
(Date:4/17/2014)... by researchers at UC Davis has shown that the ... in cell division, also boosts the mitochondrial activity to ... complex has been shown to perform both jobs. This ... to control cellular energy production, potentially advancing cancer care ... in the journal Developmental Cell . , "These ...
(Date:4/17/2014)... team led by Cesar A. Arias, M.D., Ph.D., at ... (UTHealth) has identified a new superbug that caused a ... in the April 17 issue of The New ... is part of a class of highly-resistant bacteria known ... is a major cause of hospital and community-associated infections. ...
(Date:4/17/2014)... find a colored ribbon representing a disease. A pink ribbon ... ribbon does one think of with lung cancer?, Although white ... from the disease, black may be the only one they ... cancer patients, primarily smokers between the ages of 51 to ... often felt by these patients, the emotional toll it can ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... , INDIANAPOLIS , Feb. 16 WellPoint, Inc. ... for February 23, 2010 , and announced that management will review ... 17, 2010 , at 8:30 a.m. Eastern Daylight Time (EDT). ... at least $6.00 per share, subject to its ability to ...
... ... enhance health care and medical education in more than 40 countries. With two new medical ... East. , ... 16, 2010 -- Partners Harvard Medical International (PHMI) has signed agreements with two ...
... , ... Silicones is,launching a new line of TCS 7560 and TCS ... and medical applications (support,stockings and medical equipment). These two new ... (Photo: http://www.newscom.com/cgi-bin/prnh/20100216/377913 ) , ...
... Toxic ... , ... February 16, 2010 -- Residents of a luxury Manhattan apartment building are rightfully concerned ... shows that dust in their apartments has higher levels of a carcinogen than what was ...
... ... for the Rosemere Cancer Foundation by cycling coast to coast. , ... (PRWEB) February 16, 2010 -- Last week 13 brave ... raised on a 136 mile/ 3 day charity bike ride last year in memory of ...
... ... a premier leader of the Translation, Transcription and Interpretation industries just completed its initial ... for the booming industry growth expected in the coming year. The quarter century-old ... , ...
Cached Medicine News:Health News:WellPoint To Hold Conference Call and Webcast To Discuss 2010 Financial Outlook on March 17, 2010 2Health News:WellPoint To Hold Conference Call and Webcast To Discuss 2010 Financial Outlook on March 17, 2010 3Health News:WellPoint To Hold Conference Call and Webcast To Discuss 2010 Financial Outlook on March 17, 2010 4Health News:WellPoint To Hold Conference Call and Webcast To Discuss 2010 Financial Outlook on March 17, 2010 5Health News:Partners Harvard Medical International Set to Play Key Role as Saudi Arabia Pursues Ambitious Health Care Transformation 2Health News:Bluestar Silicones Launches a New Range of Silbione(R) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications 2Health News:Toxic Construction Dust in Luxury New York Apartments Endangers Health, Angers Accident Attorneys Like David Perecman 2Health News:Plumbs Pedal Power Raises Over 6000 for Charity 2Health News:Language Service Leader Expands to Meet Booming, Global Industry Demand. 2Health News:Language Service Leader Expands to Meet Booming, Global Industry Demand. 3Health News:Language Service Leader Expands to Meet Booming, Global Industry Demand. 4Health News:Language Service Leader Expands to Meet Booming, Global Industry Demand. 5
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... BRISBANE, Calif., Oct. 27, 2011 InterMune, Inc. (NASDAQ: ... third quarter 2011 financial results at the close of the ... call and webcast will be hosted by InterMune at 4:30 ... and others may participate in the conference call by dialing ...
... 2011 Total quarterly revenues of ... grow 17 Percent, reflecting strong performance of OPANA® ER, Voltaren® Gel ... of $0.34 versus $0.46 for prior year ... from 2010 Company reaffirms 2011 guidance ...
Cached Medicine Technology:InterMune to Release Third Quarter Financial Results on November 3 2Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 2Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 3Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 4Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 5Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 6Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 7Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 8Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 9Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 10Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 11Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 12Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 13Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 14Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 15Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 16Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance 17
ROB-NEL Catheters (100% Latex-Free)...
Urethral Red Rubber Catheters (Latex)...
ULTRAMER Foley Catheter...
Silicone-Coated Foley Catheter 2-Way...
Medicine Products: